공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

아페레시스 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Apheresis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 976145
페이지 정보 영문
가격
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)


아페레시스 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Apheresis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

아페레시스의 시장 규모는 2020년 약 16억 3,900만 달러를 기록했습니다.

이 시장은 2021년에서 2026년까지 예측 기간동안 7.85%의 CAGR로 확대하고, 2026년에는 25억 8천 백만 달러에 달할 것으로 예측되고 있습니다.

아페레시스 시장은 COVID-19 치료에 있어서 플라즈마 요법에 광범위하게 적용되어 COVID-19 팬데믹 사이에 긍정적인 영향을 받을 것으로 예상됩니다. 또한, 미국 FDA는 2020년 8월, COVID-19에 감염된 입원 개인에게 회복 혈장(CCP) 요법의 긴급 사용 허가(EUA)를 허가하였다. 또한, 2020년 4월, Terumo BCT Inc.와 Marker Therapeutics AG는 18세 이상의 확진 환자를 치료하기 위해 Terumo BCT Inc.의 스펙트럼 옵티아 어페시스 시스템(Spectra Optia Apersis System)의 긴급 사용 허가(EUA)에 대한 FDA 승인을 받았다 따라서 COVID-19 환자의 치료에 있어서 아페레시스 장치의 광범위한 사용과 FDA에 의해 제품 승인의 증가를 감안할 때, 아페레시스 시장은 팬데믹 상황 속에서 긍정적인 성장을 이루었습니다.

아페레시스(Apheresis) 시장을 조사했으며, 시장 개요/제품별·아페레시스 수기별·기술별·용도별·지역별 동향/시장 진입 기업 개요 등 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장의 추진력
    • 혈액 성분 및 관련 안전 수요 증가를 초래하는 전세계 질병 부담 증가
    • 새로운 아페레시스 기술 개발에 대한 기술적 진보
    • 아페레시스 기법에 대한 상환 정책과 자금 상승
  • 시장의 억제 요인
    • 아페레시스 단계에 대한 고자본 투자
    • 숙련된 전문가의 부족
    • 혈액 오염의 위험
  • 포터의 5세력 모형

제5장 시장 세분화

  • 제품별
    • 장치
    • 일회용
  • 아페레시스 수기별
    • Leukapheresis
    • Plasmapheresis
    • Plateletpheresis
    • Erythrocytapheresis
    • 기타
  • 기술별
    • 원심 분리
    • 막 분리
  • 용도별
    • 신장 장애
    • 조혈계 질환
    • 신경학적 장애
    • 자가 면역 질환
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아 태평양
    • 중동과 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Asahi Kasei Corporation
    • B. Braun Melsungen AG
    • FRESENIUS SE&CO. KGAA(Fresenius Kabi AG)
    • Haemonetics Corporation
    • Terumo corporation(Terumo BCT)
    • Kaneka Corporation
    • Sumitomo Bakelite Company Limited(Kawasumi Laboratories Inc.)
    • Medica SPA
    • Baxter International
    • Cerus Corporation
    • Nikkiso Co. Ltd
    • Macopharma SA
    • Otsuka Holdings Co. Ltd
    • Mallinckrodt PLC

제7장 시장 기회와 동향

LYJ 21.07.30

The apheresis market was valued at approximately USD 1,639 million in 2020, and it is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period, 2021-2026.

The apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma therapy in the treatment of COVID-19 infected patients. Furthermore, in August 2020, the US FDA granted emergency use authorization (EUA) of convalescent plasma (CCP) therapy in hospitalized individuals with COVID-19. Also, in April 2020, Terumo BCT Inc. and Marker Therapeutics AG received the FDA approval for the Emergency Use Authorization (EUA) of Terumo BCT's Spectra Optia Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients aged 18 years or above with confirmed COVID-19 disease. Thus, given the wide usage of apheresis units in the treatment of COVID-19 patients and increasing product approvals by the FDA, the apheresis market enjoys a positive growth over the pandemic.

The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and a rise in the reimbursement policies and funding for apheresis procedures.

The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.

Additionally, as per the Centers for Disease Control and Prevention (CDC) 2019 report, it is estimated that about 37 million (15%) adults in the United States had chronic kidney disease (CKD). Apheresis plays a vital role in the purification of blood in patients with kidney disorders and drives the studied market. Along with these factors, the increasing product innovations and approvals have been driving the market growth. For instance, in June 2020, Fresenius Kabi AG and Fresenius Kabi USA received FDA clearance for ALYX Component Collection System, which is intended for use in blood collection establishments to collect and separate whole blood into its components. Thus, owing to the aforementioned factors, the apheresis market is expected to witness healthy growth over the forecast period.

Key Market Trends

The Hematological Disorders Segment is Expected to Grow the Fastest during the Forecast Period

Hematological disorders make a substantial contribution to the morbidity and mortality of individuals across the globe. According to the World Federation of Hemophilia report 2019, the number of people identified with hemophilia increased from 78,629 in 1999 to 324,648 in 2019 globally. Furthermore, about 157,517 people across the world are suffering from hemophilia A, and about 31,997 people are suffering from hemophilia B. Hence, owing to the increasing burden of hematological incidences and growing applications of apheresis as a treatment method for hematological disorders, the apheresis market for hematological disorders is expected to experience growth in the forecast period. The recent years brought about a rise in new options of therapeutic aphereses, such as immunoadsorption, double filtration, and cytapheresis used in the treatment of both primary and secondary autoimmune renal diseases. Additionally, as per ClinicalTrails.gov, as of January 21, 2021, there are about 47 ongoing clinical trials related to apheresis for different hematological disease development across the United States.

According to the research article published in the Journal of Thrombosis and Thrombolysis, 2020, coagulation parameters such as D-dimer, platelet count, fibrinogen, prothrombin time (PT), or activated partial thromboplastin time (aPTT) were found to be often increased in severe COVID-19 cases with an increased risk of thromboembolic complications, and thus, can indirectly impact the studied segment during the pandemic.

Furthermore, apheresis plays a very crucial role in the management of sickle cell anemia disease. As per the study titled, "Role of Emergency Automated Red Cell Exchange in Sickle Cell Crisis: A Case Report", published in November 2020, apheresis equipment was found to provide better management in red cell exchange therapeutic procedures being performed in sickle cell. Thus, owing to the aforementioned factors, the application of apheresis in treating various hematological disorders is expected to grow significantly over the forecast period.

North America Holds the Major Share in the Studied Market and is Expected to Exhibit the Same Trend over the Forecast Period

The growing burden of various ailments related to blood such as kidney diseases, metabolic diseases, cancer, and neurological disorders, the presence of established healthcare infrastructure, and high patient awareness levels are the major factors driving the growth of the studied market in North America. According to the Leukemia & Lymphoma Society (LLS), approximately every three minutes, one person in the United States is being diagnosed with blood cancer. An estimated combined total of 178,520 people in the United States were expected to be diagnosed with leukemia, lymphoma, or myeloma in 2020. The new cases of leukemia, lymphoma, and myeloma accounted for 9.9% of the estimated 1,806,590 new cancer cases diagnosed in the United States in 2020. The high incidence of target diseases thus drives the studied market growth.

In May 2020, the Department of Defense in the United States began an effort to collect 8,000 donated units of plasma from patients who have recovered from COVID-19 to support the development of an effective treatment against the disease. This effort has given rise to the adoption of plasmapheresis devices and disposables in the United States.

Additionally, the increasing product approvals and presence of most of the major players in the region play a vital role in the growth of the studied market. For instance, in October 2020, Haemonetics Corporation received the FDA approval for its NexSys PCS system with Persona technology for plasma collection based on an individual donor's body composition. Thus, the aforementioned factors are associated with the significant growth of the apheresis market in North America over the forecast period.

Competitive Landscape

The market studied is moderately competitive and is dominated by a few major players, and currently, the market is well established in many areas and has shown nascent success history. However, its full potential is yet to be determined in the developing regions. With increasing government initiatives, there is an awareness among people, which is further driving the growth of the market studied. Additionally, the strategic alliances and new product launches by the major companies are expected to drive the market growth. For instance, in January 2020, Fresenius Kabi invested EUR 30 million for the expansion of a transfusion and apheresis disposables plant in the Dominican Republic.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Disease Burden Resulting in Rise in Demand for Blood Components and Associated Safety
    • 4.2.2 Technological Advancement in Development of New Apheresis Techniques
    • 4.2.3 Rise in the Reimbursement Policies and Funding for Apheresis Procedures
  • 4.3 Market Restraints
    • 4.3.1 High Capital Investment and Costs Associated with Apheresis Procedures
    • 4.3.2 Shortage of Skilled Professionals
    • 4.3.3 Risk of Blood Contamination
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Devices
    • 5.1.2 Disposables
  • 5.2 By Apheresis Procedure
    • 5.2.1 Leukapheresis
    • 5.2.2 Plasmapheresis
    • 5.2.3 Plateletpheresis
    • 5.2.4 Erythrocytapheresis
    • 5.2.5 Other Apheresis Procedures
  • 5.3 By Technology
    • 5.3.1 Centrifugation
    • 5.3.2 Membrane Separation
  • 5.4 By Application
    • 5.4.1 Renal Disorders
    • 5.4.2 Hematological Disorders
    • 5.4.3 Neurological Disorders
    • 5.4.4 Autoimmune Disorders
    • 5.4.5 Other Applications
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Asahi Kasei Corporation
    • 6.1.2 B. Braun Melsungen AG
    • 6.1.3 FRESENIUS SE & CO. KGAA (Fresenius Kabi AG)
    • 6.1.4 Haemonetics Corporation
    • 6.1.5 Terumo corporation (Terumo BCT)
    • 6.1.6 Kaneka Corporation
    • 6.1.7 Sumitomo Bakelite Company Limited (Kawasumi Laboratories Inc.)
    • 6.1.8 Medica SPA
    • 6.1.9 Baxter International
    • 6.1.10 Cerus Corporation
    • 6.1.11 Nikkiso Co. Ltd
    • 6.1.12 Macopharma SA
    • 6.1.13 Otsuka Holdings Co. Ltd
    • 6.1.14 Mallinckrodt PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q